Design and characterization of next-gen mucosal nanovector vaccine designs

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Design and characterization of next-gen mucosal nanovector vaccine designs

Injected vaccines are strong inducers of systemic (circulating) antibodies but fail at avoiding infection and transmission of pathogens. Mucosal administration of vaccines is a solution to induce a strong mucosal immunity (in particular secreting antibodies) at the portal of entry of most of the pathogens. However, the vaccine vectors have to be especially designed and optimised for mucopenetration. Due to their original design, different to the classical LNP, these nanovectors need new protocols to evaluate: (1) encapsulation efficiency of mRNA when the use of detergent to dissolve the particle is not applicable; (2) the concentration of antigen proteins to characterise sub-unit vaccines.

In this talk, we will cover design considerations for nanoparticle, sub-unit, and other nanovectors for mucosal vaccination, and how to overcome their characterisation challenges with the latest analytical techniques.

Kevin Lance

Director, Product Management - Stunner at Unchained Labs

Kevin Lance covers the Stunner portfolio globally at Unchained Labs. His expertise includes biophysical characterization of proteins, nucleic acids, viral vectors, and LNPs. Prior to Unchained Labs, his research experience covered the fields of sustained antibody delivery and nanotechnology. He earned his PhD in Bioengineering from the joint UC Berkeley – UCSF Bioengineering Graduate Program.

Claire Monge

Research Scientist at CNRS (French National Center for Scientific Research)

Dr Claire Monge obtained a PhD of Physiology and Pharmacology from the Université Grenoble Alpes (Grenoble, France). After graduating, she worked as a postdoc at Radboud University (Nijmegen, The Netherlands) on cell bioenergetics. Back to France, she carried a 4-year project on the development of biomaterials for muscle tissue engineering. She is now a permanent research scientist at CNRS (French National Center for Scientific Research) at the Laboratory of Tissue Biology and Therapeutic Engineering in Lyon, France. She leads the NanoVec lab and carries out projects on the development of nanovectors for vaccine and biotherapy delivery at mucosal surfaces.

In 29 Days

You have registered for this webinar